Is the Cheapest Drug the Best Alternative?

Primary Psychiatry

Volumn 11, Issue 1, 2004, Pages 66-71

  Verma, Kiran ^a   Verma, Sumer ^b,c,d  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR;

BRAIN DEGENERATION; BUDGET; CHRONIC DISEASE; COST CONTROL; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG FORMULATION; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MENTAL DISEASE; OUTPATIENT; PATIENT COMPLIANCE; PRESCRIPTION; REIMBURSEMENT; RELAPSE; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT FAILURE;

EID: 1842560306     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Raisch DW. Understanding quality-adjusted life years and their application to pharmacoeconomic research. Ann Pharmacother. 2000;7:906-914.
2. Novartis Pharmaceuticals Corporation. Novartis Pharmacy Benefit Report: 1998 Trends and Forecasts. East Hanover, NJ: Novartis Pharmaceutical Corporation; 1998.
3. Levit KR, Lazenby HC, Braden BR. National health care spending trends in 1996. Health Affairs. 1998;1:35-51.
4. Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees - a call to action. N Engl J Med. 1999;340:722-728.
5. Bauman NL. Playing doctor in Tallahassee: how lawmakers' efforts to save money may threaten quality of care for mentally ill Medicaid patients. James Madison Institute Policy Report #37. Tallahassee, FL: James Madison Institute; 2002.
6. Levy RA, Cocks D. Component Management Fails to Save Health Care System Costs: The Case of Restrictive Formularies. Reston, VA: National Pharmaceutical Council; 2000.
7. The Lewin Group. Health Plan Benefit Barriers to Access to Pharmaceutical Therapies for Behavioral Health: Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1998.
8. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655.
9. Soumerai SB, Ross-Degnan D, Avorn J, Mclaughlin TJ, Choodnovskiy I. Effects of Medicaid drug payment limits on admission to hospital and nursing homes. N Engl J Med. 1991;325:102-107.
10. Graham M. NMHA policy positions on restrictive formularies - revised. August, 1998. Available at: www.nmha.org/positions/pso32698b.cfm. Accessed November 16, 2003.
11. Johnston RE, Goodman MJ, Hornbrook MC, Eldredge MD. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs reserved and on the health status of elderly HMO members. Health Serv Res. 1997;1:103-122.
12. Stock AJ, Koefoed L. Therepeutic interchange of fluoxetine and sertraline experience in the clinical setting. Am J Hosp Pharm. 1994;51:2279-2281.
13. Svarstad BL, Schireman TI, Sweeney TK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805-811.
14. Goldman HH, Adams NH, Taube CA. Deinstitutionalization: the data demythologized. Hosp Community Psychiatry. 1983;2:129-134.
15. Witkin MJ, Atay J, Manderscheid RW. Trends in state and county mental hospitals in the U.S. from 1970 to 1992. Psychiatr Serv. 1996;10:1079-1081.
16. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21:419-429.
17. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;10:968-976.
18. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry. 2001;16(suppl 1):S62-S70.
19. Kane J. Olanzapine in the long-term treatment of schizophrenia. Br J Psychiatry. 1999;37(suppl):26-29.
20. Aquila R, Santos G, Malamud TJ, McCrory D. The rehabilitation alliance in practice: the clubhouse connection. Psychiatr Rehabil J. 1999;23:19-23.
21. Keck PE, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility; and suicidality in patients with schizophrenia. J Clin Psych. 2000;61(suppl 3):4-9.
22. Blieden, N, Flinders S, Hawkins K, Reid M, Alphs LD, Arfken CL. Health status and health-care costs for publicly funded patients with schizophrenia started on Clozapine. Psychiatr Serv. 1998;49:1590-1593.
23. Tunis SL. The impact of schizophrenic patient functionality on service utilization and cost. Am J Manag Care. 1999;5(suppl 10):S583-S590.
24. Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacol Bull. 1998;3:373-382.
25. Martin BC, Miller LS. Expenditures for treating schizophrenia: a population-based study of Georgia Medicaid recipients. Schizophr Bull. 1998;3:479-488.
26. National Institute of Diabetes and Digestive Kidney Diseases. Nation's health report shows widespread increase in diabetes: National Diabetes Education Program responds. January 25, 2000. Available at: http://www.niddk.nih.gov/welcome/releases/1_25_00_widespread.htm. Accessed November 16, 2003.
27. Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry. 2001;6:848-856.
28. Sylvester B. APA: Increased prevalence of diabetes among patients receiving antipsychotic drugs. May 20, 2003. Available at: www.docguide.com/news/content.nsf/news/8525697700573E1885256D2C006AAC49. Accessed November 16, 2003.
29. Business Wire News Portal. Eli Lilly and Company: Risk factors for diabetes in people with schizophrenia mirror those of general population. May 19, 2003. Available at: www.businesswire.com/webbox/bw.051903/231395405.htm. Accessed November 15, 2003.
30. About.com Mental Health Resources. Antipsychotic drugs may reduce diabetic risk in mentally ill. May 19, 2003. Available at: mental-health.about.com/cs/mindandbody/a/szdiab503.htm. Accessed November 14, 2003.
31. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psych. 2002;2:117-119.